IL273242B2 - 6-chloro-3-(4,2-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4 (3h)-one and derivative compounds, preparations containing them and their uses - Google Patents
6-chloro-3-(4,2-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4 (3h)-one and derivative compounds, preparations containing them and their usesInfo
- Publication number
- IL273242B2 IL273242B2 IL273242A IL27324220A IL273242B2 IL 273242 B2 IL273242 B2 IL 273242B2 IL 273242 A IL273242 A IL 273242A IL 27324220 A IL27324220 A IL 27324220A IL 273242 B2 IL273242 B2 IL 273242B2
- Authority
- IL
- Israel
- Prior art keywords
- disease
- compound
- effective amount
- cancer
- cpt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558323P | 2017-09-13 | 2017-09-13 | |
| PCT/US2018/050689 WO2019055528A1 (en) | 2017-09-13 | 2018-09-12 | NEW COMPOUND WITH SMALL MOLECULES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273242A IL273242A (en) | 2020-04-30 |
| IL273242B1 IL273242B1 (en) | 2023-04-01 |
| IL273242B2 true IL273242B2 (en) | 2023-08-01 |
Family
ID=65723058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273242A IL273242B2 (en) | 2017-09-13 | 2020-03-11 | 6-chloro-3-(4,2-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4 (3h)-one and derivative compounds, preparations containing them and their uses |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11186550B2 (enExample) |
| EP (1) | EP3681874B1 (enExample) |
| JP (1) | JP7170341B2 (enExample) |
| KR (1) | KR102644045B1 (enExample) |
| CN (1) | CN111372921B (enExample) |
| AU (1) | AU2018331371C1 (enExample) |
| CA (1) | CA3075649A1 (enExample) |
| IL (1) | IL273242B2 (enExample) |
| WO (1) | WO2019055528A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11186550B2 (en) | 2017-09-13 | 2021-11-30 | Cerepeut, Inc. | Small molecule compound |
| US12454514B2 (en) | 2019-02-27 | 2025-10-28 | Cerepeut, Inc. | Quinazolinone compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006501180A (ja) | 2002-06-27 | 2006-01-12 | ジ エンドウメント フォア リサーチ イン ヒューマン バイオロジー インコーポレイテッド | Ａｌｄｈの阻害に有効な化合物 |
| US20050038051A1 (en) * | 2003-06-09 | 2005-02-17 | Jodi Nunnari | Novel molecules for regulating cell death |
| AU2006303037A1 (en) | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co Kgaa | Chromenones and their use as modulators of metabotropic glutamate receptors |
| US8759097B2 (en) * | 2011-04-19 | 2014-06-24 | University of Pittsburgh—of the Commonwealth System of Higher Eduction | Inhibition of dynamin related protein 1 to promote cell death |
| US9492450B2 (en) * | 2011-04-19 | 2016-11-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of dynamin related protein 1 to promote cell death |
| JP2013142070A (ja) | 2012-01-11 | 2013-07-22 | Nihon Univ | ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服 |
| CN105008515A (zh) | 2012-12-28 | 2015-10-28 | 小利兰·斯坦福大学托管委员会 | 用于治疗线粒体疾病和用于使细胞分化成神经元的组合物和方法 |
| US9289448B2 (en) | 2013-03-15 | 2016-03-22 | Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating alzheimer's disease and other tauopathies |
| US9730935B2 (en) * | 2013-12-13 | 2017-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting a non-canonical notch signaling pathway for cancer treatment |
| GB201522232D0 (en) | 2015-12-16 | 2016-01-27 | Liverpool School Tropical Medicine | Combination product |
| US11186550B2 (en) | 2017-09-13 | 2021-11-30 | Cerepeut, Inc. | Small molecule compound |
-
2018
- 2018-09-12 US US16/647,383 patent/US11186550B2/en active Active
- 2018-09-12 CA CA3075649A patent/CA3075649A1/en active Pending
- 2018-09-12 EP EP18856020.5A patent/EP3681874B1/en active Active
- 2018-09-12 CN CN201880070789.4A patent/CN111372921B/zh active Active
- 2018-09-12 JP JP2020515882A patent/JP7170341B2/ja active Active
- 2018-09-12 AU AU2018331371A patent/AU2018331371C1/en active Active
- 2018-09-12 WO PCT/US2018/050689 patent/WO2019055528A1/en not_active Ceased
- 2018-09-12 KR KR1020207010525A patent/KR102644045B1/ko active Active
-
2020
- 2020-03-11 IL IL273242A patent/IL273242B2/en unknown
-
2021
- 2021-11-29 US US17/537,142 patent/US11912669B2/en active Active
-
2024
- 2024-02-26 US US18/587,753 patent/US12404251B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220340534A1 (en) | 2022-10-27 |
| EP3681874A4 (en) | 2021-01-13 |
| US20240246919A1 (en) | 2024-07-25 |
| US11912669B2 (en) | 2024-02-27 |
| IL273242B1 (en) | 2023-04-01 |
| EP3681874B1 (en) | 2022-04-06 |
| US20200216400A1 (en) | 2020-07-09 |
| WO2019055528A1 (en) | 2019-03-21 |
| EP3681874A1 (en) | 2020-07-22 |
| US12404251B2 (en) | 2025-09-02 |
| KR102644045B1 (ko) | 2024-03-05 |
| IL273242A (en) | 2020-04-30 |
| AU2018331371C1 (en) | 2024-05-09 |
| JP2020533399A (ja) | 2020-11-19 |
| AU2018331371B2 (en) | 2024-02-15 |
| JP7170341B2 (ja) | 2022-11-14 |
| CA3075649A1 (en) | 2019-03-21 |
| CN111372921B (zh) | 2023-12-01 |
| AU2018331371A1 (en) | 2020-04-02 |
| US11186550B2 (en) | 2021-11-30 |
| KR20200053560A (ko) | 2020-05-18 |
| CN111372921A (zh) | 2020-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adhihetty et al. | Effect of denervation on mitochondrially mediated apoptosis in skeletal muscle | |
| US12404251B2 (en) | Small molecule compound | |
| JPH11514643A (ja) | ロタマーゼ酵素活性阻害剤 | |
| CN101631547A (zh) | 使用地莫本和多奈哌齐治疗阿尔茨海默病的组合疗法 | |
| Mamedov et al. | New tetrahydro-isoquinoline derivatives as cholinesterase and α-glycosidase inhibitors: Synthesis, characterization, molecular docking & dynamics, ADME prediction, in vitro cytotoxicity and enzyme inhibition studies | |
| IL305332A (en) | A combination of ABT-199 and achmetalstat for the treatment of AML | |
| JPH08502488A (ja) | 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性 | |
| Yajing et al. | Approved drugs and natural products at clinical stages for treating Alzheimer’s disease | |
| Tiwari et al. | Elucidation of abnormal extracellular regulated kinase (ERK) signaling and associations with syndromic and non-syndromic autism | |
| Chen et al. | An in vitro and in vivo study: Valencene protects cartilage and alleviates the progression of osteoarthritis by anti-oxidative stress and anti-inflammatory effects | |
| IL256055A (en) | Using h3k9me3 modulation to increase cognitive function | |
| KR20100116177A (ko) | 근골격-관련 장애의 치료에서 헤지호그 효능제의 용도 | |
| CN105362273A (zh) | 7-烷氧基防己诺林碱类化合物在制备治疗和改善抑郁症状的药物中的用途 | |
| Liu et al. | Protective Effect of Topiroxostat on Myocardial Injury Induced by Lipopolysaccharide | |
| IL299761A (en) | GABAA alpha 5 agonist polymorphs and methods of use for the treatment of cognitive impairment | |
| Zhang et al. | 13-methylpalmatine alleviates myocardial ischemia/reperfusion injury by potentially targeting the C5a-C5aR1 axis to inhibit neutrophil extracellular trap formation | |
| Pang et al. | A Novel Oxo‐Palmatine Derivative 2q as Potent Reversal Agents Against Alzheimer's Disease | |
| CN114874220B (zh) | 一种8-胺基苯磺酰胺取代的色胺酮类衍生物及其制备和应用 | |
| US20220047550A1 (en) | Compounds and methods for the treatment of degenerative disorders | |
| Muthuraman et al. | Current Perspectives in the Management of Neurodegenerative Alzheimer’s Disease: Preclinical and Clinical Status | |
| IL313615A (en) | Use of a class of 1,4-dihydro-naphthyridine derivatives in treatment of tumors | |
| Merino | Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for Acute Myeloid Leukemia |